• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Destruxin B

Destruxin B

Product ID D183745
Cas No. 2503-26-6
Purity ≥96%
Product Unit SizeCostQuantityStock
100 µg $102.00 In stock
1 mg $613.00 In stock
5 mg $2,453.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Destruxin B, a cyclic depsipeptide, is a secondary metabolite isolated from the fungus Metarhizium anisopliae. Each of the mycotoxins, destruxin A, B, and E, were individually found to display antitumor effects on leukemic cells in vitro. In addition, each destruxin was found to produce antiproliferative effects in colon cancer cells and to inhibit the migration and tube formation of human endothelial cells. Although the inhibition of vacuolar-type ATPase by destruxin B has been found to be weaker than bafilomycin A1, inhibition by destruxin B was found to be readily reversible, which makes it more useful as a probe of V-ATPase function. In human colorectal cancer cells destruxin B treatment resulted in suppressed proliferation and induced cell cycle arrest. Administration of destruxin B to human non-Hodgkin lumphoma cells resulted in apoptosis induced by attenuation of the mitochondrial membrane potential.

Product Info

Cas No.

2503-26-6

Purity

≥96%

Formula

C30H51N5O7

Formula Wt.

593.77

Chemical Name

Destruxin B

IUPAC Name

16-butan-2-yl-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone

Synonym

MLS002702090; AC1L8LE6; MEGxm0_000393

Melting Point

230-240°C

Appearance

White powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D183745 MSDS PDF

Info Sheet

D183745 Info Sheet PDF

References

Yeh CT, Rao YK, Ye M, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. PMID: 22465936.

Odier F, Vey A, Bureau JP. In vitro effect of fungal cyclodepsipeptides on leukemic cells: study of destruxins A, B, and E. Biol Cell. 1992;74(3):267-271. PMID: 1628110.

Dornetshuber-Fleiss R, Heffeter P, Mohr T, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol. 2013 Aug 1;86(3):361-377. PMID: 23747344.

Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1358-1365. PMID: 7802670.

Chao PZ, Chin YP, Hsu IU, et al. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol In Vitro. 2013 Sep;27(6):1870-1876. PMID: 23751424.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C002045

    Oxazolidine Cabazitaxel

    Synthesis impurity

    ≥95%
  • V1872

    Vesicular Stomatitis Virus Peptide

    Peptide fragment of VSV; LDLR agonist.

    ≥95%
  • P3348

    Pimecrolimus

    Calcineurin inhibitor, potential TRPV1 agonist....

    ≥99%
  • L493400

    LMK-235

    Selective HDAC4 and HDAC5 inhibitor.

    ≥98%
  • K1653

    Kendomycin

    Macrolide; ET antagonist, proteasome inhibitor....

    ≥98%
  • B3280

    Bis(salicyl) Fumarate

    Aspirin analog; hemoglobin chain cross-linker.<...

    ≥98%
  • B5648

    Bombesin

    GRP analog, found in Bombina; bombesin and GRP ...

    ≥95%
  • S8110

    Sucralfate

    Antacid; pepsin inhibitor. Assay (Polysaccharid...

    Assay (Polysaccharide sulfate) 30-38%
  • P698583

    Prostaglandin E2

    principal metabolic product of COX-2

    ≥98%
  • L0211

    Lactulose

    Synthetic non-digestible disaccharide.

    ≥99%
  • T2933

    4-Thiouridine

    Modified nucleotide used for labeling DNA; DNA ...

    ≥99%
  • A016493

    4-Aminopyrimidine

    Building block

    ≥98%
  • A6933

    Aristolochic Acid B

    Found in Aristolochia and Radix; potential PLA2...

    ≥95%
  • V7200

    VS-5584

    PI3K inhibitor.

    ≥98%
  • A480010

    AM630

    CB2 receptor antagonist.

    ≥97%
  • S1612

    Sedanolide

    Phthalide found in celery seeds; COX-1, COX-2, ...

    ≥98%
  • R5974

    Rosuvastatin Calcium

    Statin; HMG-CoA reductase inhibitor, potential ...

    ≥98%
  • S8151

    Sumatriptan Succinate

    Tryptamine; 5-HT1B/1D agonist, TRPV1 antagonist...

    ≥99%
  • B5870

    Borrelidin

    Macrolide; threonyl-tRNA synthetase/ligase inhi...

    ≥99%
  • A4854

    β-Amyloid Peptide (1-42), rat

    Endogenous APP peptide cleavage product, primar...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only